Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Basal Cell 5Medulloblastoma 4Recurrence 3Basal Cell Nevus Syndrome 2Thrombocytosis 1Thrombocythemia, Essential 1Stomach Neoplasms 1Skin Neoplasms 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

dacetuzumab 2Bortezomib 2sonidegib 1ruxolitinib 1ficlatuzumab 1Vorinostat 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Lenalidomide 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hemorrhagic Disorders × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡